FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118292205> ?p ?o ?g. }

• W3118292205 endingPage "S786" @default.
• W3118292205 startingPage "S786" @default.
• W3118292205 abstract "Abstract Background Numerous number of studies have found a positive correlation between delayed appropriate antibiotic therapy and negative clinical outcomes (NCO) in Gram-negative bacterial infections (GNBI). The combination of meropenem with vaborbactam (MVB) received Food and Drug Administration approval for the treatment of complicated urinary tract infections and acute pyelonephritis caused by susceptible organisms in August 2017. We sought to determine the impact of delayed appropriate therapy with MVB on NCO among patients with GNBI. Methods Multi-center, retrospective cohort study from October 2017 to March 2020. We included adult patients treated with MVB for &gt;72 hours. We excluded patients who received alternative appropriate antibiotics for GNB prior to MVB and patients with unknown dates for index culture. NCO were defined as 30-day mortality and/or microbiological recurrence. All outcomes were measured from MVB start date. Classification and regression tree analysis (CART) was used to identify the time breakpoint (BP) that delineates the risk of NCO. Multivariable logistic regression analysis (MLR) was used to examine the independent association between the CART-derived-BP and NCO. Variables were retained in the model if P&lt; 0.2 and removed in a backward stepwise approach. Results A total of 86 patients were included from 13 institutions in the United States: median(IQR) age 55 (37-67) years, 67% male, and 48% Caucasian. Median(IQR) APACHE II and Charlson Comorbidity index scores were 18(11-26) and 4(2-6), respectively. Common sources of infection were respiratory (37%) and intra-abdominal (21%). The most common pathogens were carbapenem-resistant Enterobacterales (83%). CART-derived BP between early and delayed treatment was 48 hours, where NCO was increased (36% vs.7%; P=0.04). Delayed MVB initiation was independently associated with NCO in the MLR (aOR=7.4, P=0.02). Results of Regression Analysis of Variables Associated With Negative Clinical Outcomes and Delayed Appropriate Therapy with Meropenem-vaborbactam Conclusion Our results suggest that delaying appropriate antibiotic therapy with MVB for &gt;48 hours significantly increases the risk of NCO in patients with GNBI. Clinicians must ensure timely administration of MVB to assure best outcomes in patients with GNBI. Disclosures Kevin W. Garey, PharMD, MS, FASHP, Merck & Co. (Grant/Research Support, Scientific Research Study Investigator) Michael J. Rybak, PharmD, MPH, PhD, Paratek (Grant/Research Support)" @default.
• W3118292205 created "2021-01-18" @default.
• W3118292205 creator A5005204544 @default.
• W3118292205 creator A5005269906 @default.
• W3118292205 creator A5021111881 @default.
• W3118292205 creator A5033085593 @default.
• W3118292205 creator A5034161489 @default.
• W3118292205 creator A5035784199 @default.
• W3118292205 creator A5040605612 @default.
• W3118292205 creator A5040952634 @default.
• W3118292205 creator A5044691547 @default.
• W3118292205 creator A5051114234 @default.
• W3118292205 creator A5051367948 @default.
• W3118292205 creator A5052246119 @default.
• W3118292205 creator A5052991025 @default.
• W3118292205 creator A5054876931 @default.
• W3118292205 creator A5056054109 @default.
• W3118292205 creator A5065333422 @default.
• W3118292205 creator A5071231332 @default.
• W3118292205 creator A5071940344 @default.
• W3118292205 creator A5073042611 @default.
• W3118292205 creator A5073613133 @default.
• W3118292205 creator A5082410774 @default.
• W3118292205 creator A5084829703 @default.
• W3118292205 creator A5087948620 @default.
• W3118292205 date "2020-10-01" @default.
• W3118292205 modified "2023-10-14" @default.
• W3118292205 title "1575. Predictors of Negative Clinical Outcomes among Patients treated with Meropenem-Vaborbactam for Serious Gram-Negative Bacterial Infections: Impact of Delayed Appropriate Antibiotic Selection" @default.
• W3118292205 doi "https://doi.org/10.1093/ofid/ofaa439.1755" @default.
• W3118292205 hasPublicationYear "2020" @default.
• W3118292205 type Work @default.
• W3118292205 sameAs 3118292205 @default.
• W3118292205 citedByCount "0" @default.
• W3118292205 crossrefType "journal-article" @default.
• W3118292205 hasAuthorship W3118292205A5005204544 @default.
• W3118292205 hasAuthorship W3118292205A5005269906 @default.
• W3118292205 hasAuthorship W3118292205A5021111881 @default.
• W3118292205 hasAuthorship W3118292205A5033085593 @default.
• W3118292205 hasAuthorship W3118292205A5034161489 @default.
• W3118292205 hasAuthorship W3118292205A5035784199 @default.
• W3118292205 hasAuthorship W3118292205A5040605612 @default.
• W3118292205 hasAuthorship W3118292205A5040952634 @default.
• W3118292205 hasAuthorship W3118292205A5044691547 @default.
• W3118292205 hasAuthorship W3118292205A5051114234 @default.
• W3118292205 hasAuthorship W3118292205A5051367948 @default.
• W3118292205 hasAuthorship W3118292205A5052246119 @default.
• W3118292205 hasAuthorship W3118292205A5052991025 @default.
• W3118292205 hasAuthorship W3118292205A5054876931 @default.
• W3118292205 hasAuthorship W3118292205A5056054109 @default.
• W3118292205 hasAuthorship W3118292205A5065333422 @default.
• W3118292205 hasAuthorship W3118292205A5071231332 @default.
• W3118292205 hasAuthorship W3118292205A5071940344 @default.
• W3118292205 hasAuthorship W3118292205A5073042611 @default.
• W3118292205 hasAuthorship W3118292205A5073613133 @default.
• W3118292205 hasAuthorship W3118292205A5082410774 @default.
• W3118292205 hasAuthorship W3118292205A5084829703 @default.
• W3118292205 hasAuthorship W3118292205A5087948620 @default.
• W3118292205 hasBestOaLocation W31182922051 @default.
• W3118292205 hasConcept C10936531 @default.
• W3118292205 hasConcept C126322002 @default.
• W3118292205 hasConcept C151956035 @default.
• W3118292205 hasConcept C167135981 @default.
• W3118292205 hasConcept C170964787 @default.
• W3118292205 hasConcept C2778384902 @default.
• W3118292205 hasConcept C2779375183 @default.
• W3118292205 hasConcept C501593827 @default.
• W3118292205 hasConcept C71924100 @default.
• W3118292205 hasConcept C72563966 @default.
• W3118292205 hasConcept C77411442 @default.
• W3118292205 hasConcept C86803240 @default.
• W3118292205 hasConcept C89423630 @default.
• W3118292205 hasConcept C90924648 @default.
• W3118292205 hasConcept C94665300 @default.
• W3118292205 hasConceptScore W3118292205C10936531 @default.
• W3118292205 hasConceptScore W3118292205C126322002 @default.
• W3118292205 hasConceptScore W3118292205C151956035 @default.
• W3118292205 hasConceptScore W3118292205C167135981 @default.
• W3118292205 hasConceptScore W3118292205C170964787 @default.
• W3118292205 hasConceptScore W3118292205C2778384902 @default.
• W3118292205 hasConceptScore W3118292205C2779375183 @default.
• W3118292205 hasConceptScore W3118292205C501593827 @default.
• W3118292205 hasConceptScore W3118292205C71924100 @default.
• W3118292205 hasConceptScore W3118292205C72563966 @default.
• W3118292205 hasConceptScore W3118292205C77411442 @default.
• W3118292205 hasConceptScore W3118292205C86803240 @default.
• W3118292205 hasConceptScore W3118292205C89423630 @default.
• W3118292205 hasConceptScore W3118292205C90924648 @default.
• W3118292205 hasConceptScore W3118292205C94665300 @default.
• W3118292205 hasIssue "Supplement_1" @default.
• W3118292205 hasLocation W31182922051 @default.
• W3118292205 hasLocation W31182922052 @default.
• W3118292205 hasLocation W31182922053 @default.
• W3118292205 hasOpenAccess W3118292205 @default.
• W3118292205 hasPrimaryLocation W31182922051 @default.
• W3118292205 hasRelatedWork W2413686299 @default.
• W3118292205 hasRelatedWork W2969962500 @default.
• W3118292205 hasRelatedWork W2980765219 @default.
• W3118292205 hasRelatedWork W2994738067 @default.

• next